<DOC>
	<DOCNO>NCT00755170</DOCNO>
	<brief_summary>This trial evaluate efficacy safety metronomic vinorelbine bevacizumab combination patient pretreated , advance non small cell lung cancer</brief_summary>
	<brief_title>Metronomic Vinorelbine Bevacizumab Patients With Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Intravenous ( IV ) vinorelbine standard chemotherapy option treatment metastatic NSCLC , either alone combination agent CDDP Carboplatin overall response rate ( ORR ) 15-35 % 1st line treatment le 10 % salvage treatment . For past year vinorelbine available per o ( po ) administration acceptable reliable pharmacokinetic profile bioavailability approximately 40 % IV dose . In randomized phase II study IV po vinorelbine show comparable response overall survival rate . The low dose metronomic chemotherapy administer short interval show vitro vivo antiangiogenic effect . Bevacizumab well know anti-angiogenic agent . Recently , phase III study 1st line treatment patient advance metastatic NSCLC show addition bevacizumab platinum-based regimen provide survival benefit . This study evaluate combination metronomic vinorelbine bevavizumab 2nd line treatment NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm , metastatic ( stage IV ) non small cell lung cancer One previous platinum base chemotherapy regimen without taxanes metastatic NSCLC Measurable disease , define least 1 bidimensionally measurable lesion ≥ 20 X 10 mm Age ≥ 18 year Performance status ( WHO ) 02 Life expectancy least 12 week Adequate bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥ 100,000/mm3 , Hgb ≥ 11 g/dL ) , liver ( Bilirubin ≤ 1.5 upper normal limit , SGOT/SGPT ≤ 2.5 upper normal limit absence liver metastases ≤ 5 upper normal limit presence liver metastasis ) , renal function ( Creatinine ≤ 1,5 upper normal limit ) Patients must able understand nature study Written inform consent Second primary malignancy , except nonmelanoma skin cancer . Pregnant lactate woman Any serious , uncontrolled comorbidity investigator 's judgment Uncontrolled infection Any sustain chronic toxicity &gt; grade 2 accord NCI CTCAE ( version 3.0 ) Brain metastasis , except radiate asymptomatic Radiotherapy within previous 4 week Previous radiotherapy measurable lesion Proteinuria ≥ 500 mgr protein daily Hemoptysis &gt; 10 cc per event Clinically significant hematemesis Centrally locate lesion contact major vessel Pulmonary lesion cavitation Documented hemorrhagic diathesis coagulation disorder Cardiovascular disease ( class IIIV NYHA congestive heart failure , myocardial infarction within previous 4 month , unstable angina , LVEF &lt; normal , ventricular arrhythmia , uncontrolled hypertension ) Thrombotic event within previous 6 month Concurrent use aspirin &gt; 325 mgr daily , low molecular weight heparin therapeutic dose , warfarin acenocoumarol , nonsteroid antiinflammatory agent Concurrent treatment anticancer drug Major surgical procedure within previous 4 week Serum Να+ &lt; 120mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Vinorelbine</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>